Literature DB >> 2438231

Fertility after chemotherapy for male and female germ cell tumours.

G J Rustin, D Pektasides, K D Bagshawe, E S Newlands, R H Begent.   

Abstract

Gonadal function was assessed in fifty-nine men and thirty-one women who had successfully completed chemotherapy with the POMB/ACE regimen for germ cell tumours. Seventeen (81%) of the twenty-one men who had not received paraaortic radiotherapy, whose original tumour bulk was less than 5 cm and whose duration of chemotherapy was less than 6 months, recovered spermatogenesis compared with twelve (32%) of thirty-eight patients who had either larger tumour masses or longer courses of chemotherapy, or both. All but one of the seventeen women in whom menstruation could have been expected to recur are now menstruating. This study suggests that the great majority of patients treated with POMB/ACE chemotherapy for germ cell tumours will recover fertility.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438231     DOI: 10.1111/j.1365-2605.1987.tb00208.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  4 in total

Review 1.  Preventable causes of male infertility.

Authors:  S T Thompson
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

2.  Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

Authors:  A M Gillespie; P C Lorigan; C R Radstone; J C Waterhouse; R E Coleman; B W Hancock
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy.

Authors:  A M Gillespie; S Kumar; B W Hancock
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

4.  Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study.

Authors:  J Gaffan; L Holden; E S Newlands; D Short; S Fuller; R H J Begent; G J S Rustin; M J Seckl
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.